Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 1/2 × Adenoviridae Infections × pembrolizumab × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Conditions

Carcinoma, Non-Small-Cell Lung 85 Melanoma 66 Squamous Cell Carcinoma of Head and Neck 41 Neoplasms 40 Neoplasm Metastasis 40 Lung Neoplasms 33 Colorectal Neoplasms 32 Carcinoma, Renal Cell 32 Breast Neoplasms 31 Triple Negative Breast Neoplasms 30 Carcinoma, Transitional Cell 25 Stomach Neoplasms 23 Ovarian Neoplasms 23 Head and Neck Neoplasms 22 Esophageal Neoplasms 18 Uterine Cervical Neoplasms 16 Parkinson Disease 4, Autosomal Dominant Lewy Body 16 Pancreatic Neoplasms 16 Carcinoma, Hepatocellular 15 Urinary Bladder Neoplasms 14 Endometrial Neoplasms 14 Small Cell Lung Carcinoma 13 Recurrence 11 Carcinoma 11 Sarcoma 10 Prostatic Neoplasms 10 Lymphoma 10 Glioblastoma 10 Mesothelioma 8 Fallopian Tube Neoplasms 8

Interventions

pembrolizumab 1 liposomal doxorubicin 1 fludarabine phosphate 1 atezolizumab 1 Gemcitabine 1 Albumin-Bound Paclitaxel 1 130-nm albumin-bound paclitaxel 1 1-dodecylpyridoxal 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT05271318 2025-11-03

PROTA

TILT Biotherapeutics Ltd.

Phase 1/2 Recruiting

Adenoviridae Infections

Data powered by HemOnc (CC BY 4.0) Colophon ⚡